Cargando…

Difference in the effects of switching from Candesartan to Olmesartan or Telmisartan to Olmesartan in hypertensive patients with type 2 diabetes: the COTO study

PURPOSE: This open-label controlled study compared the therapeutic efficacy of three representative angiotensin II receptor blockers (ARBs) in hypertensive patients with type 2 diabetes attending a hospital outpatient clinic. The primary measure in this study was morning home blood pressure (BP). PA...

Descripción completa

Detalles Bibliográficos
Autores principales: Daikuhara, Hiroyuki, Fukunaga, Kensaku, Ohshima, Tomie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3933665/
https://www.ncbi.nlm.nih.gov/pubmed/24600204
http://dx.doi.org/10.2147/DDDT.S53253
_version_ 1782304964069031936
author Daikuhara, Hiroyuki
Fukunaga, Kensaku
Ohshima, Tomie
author_facet Daikuhara, Hiroyuki
Fukunaga, Kensaku
Ohshima, Tomie
author_sort Daikuhara, Hiroyuki
collection PubMed
description PURPOSE: This open-label controlled study compared the therapeutic efficacy of three representative angiotensin II receptor blockers (ARBs) in hypertensive patients with type 2 diabetes attending a hospital outpatient clinic. The primary measure in this study was morning home blood pressure (BP). PATIENTS AND METHODS: Two studies were done concurrently to investigate the effects of switching from two different ARBs to olmesartan. Patients prescribed candesartan (8 mg once daily in the morning) or telmisartan (40 mg once daily in the morning) for 16 weeks were switched to olmesartan (20 mg once daily in the morning) for 16 weeks. Then, they were switched back to candesartan (CO group) or telmisartan (TO group) for another 16 weeks. RESULTS: Data from all patients in the CO group (n=165) and the TO group (n=152) were analyzed. Clinic and morning home BP and urinary albumin levels showed a significant decrease from baseline at 16 weeks after switching to olmesartan in both the CO and the TO group (clinic BP, morning home diastolic BP, and urinary albumin, P<0.05; morning home systolic BP, P<0.01). In contrast, clinic BP, morning home BP, and urinary albumin were significantly increased again 16 weeks after switching back to candesartan or telmisartan (clinic BP, morning home diastolic BP, and urinary albumin, P<0.05; morning home systolic BP, P<0.01). No subjects experienced an adverse reaction that required withdrawal from the study. No adverse reactions attributable to the study drugs were observed. CONCLUSION: Olmesartan is a promising ARB for BP control in hypertensive type 2 diabetics.
format Online
Article
Text
id pubmed-3933665
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-39336652014-03-05 Difference in the effects of switching from Candesartan to Olmesartan or Telmisartan to Olmesartan in hypertensive patients with type 2 diabetes: the COTO study Daikuhara, Hiroyuki Fukunaga, Kensaku Ohshima, Tomie Drug Des Devel Ther Original Research PURPOSE: This open-label controlled study compared the therapeutic efficacy of three representative angiotensin II receptor blockers (ARBs) in hypertensive patients with type 2 diabetes attending a hospital outpatient clinic. The primary measure in this study was morning home blood pressure (BP). PATIENTS AND METHODS: Two studies were done concurrently to investigate the effects of switching from two different ARBs to olmesartan. Patients prescribed candesartan (8 mg once daily in the morning) or telmisartan (40 mg once daily in the morning) for 16 weeks were switched to olmesartan (20 mg once daily in the morning) for 16 weeks. Then, they were switched back to candesartan (CO group) or telmisartan (TO group) for another 16 weeks. RESULTS: Data from all patients in the CO group (n=165) and the TO group (n=152) were analyzed. Clinic and morning home BP and urinary albumin levels showed a significant decrease from baseline at 16 weeks after switching to olmesartan in both the CO and the TO group (clinic BP, morning home diastolic BP, and urinary albumin, P<0.05; morning home systolic BP, P<0.01). In contrast, clinic BP, morning home BP, and urinary albumin were significantly increased again 16 weeks after switching back to candesartan or telmisartan (clinic BP, morning home diastolic BP, and urinary albumin, P<0.05; morning home systolic BP, P<0.01). No subjects experienced an adverse reaction that required withdrawal from the study. No adverse reactions attributable to the study drugs were observed. CONCLUSION: Olmesartan is a promising ARB for BP control in hypertensive type 2 diabetics. Dove Medical Press 2014-02-17 /pmc/articles/PMC3933665/ /pubmed/24600204 http://dx.doi.org/10.2147/DDDT.S53253 Text en © 2014 Daikuhara et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Daikuhara, Hiroyuki
Fukunaga, Kensaku
Ohshima, Tomie
Difference in the effects of switching from Candesartan to Olmesartan or Telmisartan to Olmesartan in hypertensive patients with type 2 diabetes: the COTO study
title Difference in the effects of switching from Candesartan to Olmesartan or Telmisartan to Olmesartan in hypertensive patients with type 2 diabetes: the COTO study
title_full Difference in the effects of switching from Candesartan to Olmesartan or Telmisartan to Olmesartan in hypertensive patients with type 2 diabetes: the COTO study
title_fullStr Difference in the effects of switching from Candesartan to Olmesartan or Telmisartan to Olmesartan in hypertensive patients with type 2 diabetes: the COTO study
title_full_unstemmed Difference in the effects of switching from Candesartan to Olmesartan or Telmisartan to Olmesartan in hypertensive patients with type 2 diabetes: the COTO study
title_short Difference in the effects of switching from Candesartan to Olmesartan or Telmisartan to Olmesartan in hypertensive patients with type 2 diabetes: the COTO study
title_sort difference in the effects of switching from candesartan to olmesartan or telmisartan to olmesartan in hypertensive patients with type 2 diabetes: the coto study
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3933665/
https://www.ncbi.nlm.nih.gov/pubmed/24600204
http://dx.doi.org/10.2147/DDDT.S53253
work_keys_str_mv AT daikuharahiroyuki differenceintheeffectsofswitchingfromcandesartantoolmesartanortelmisartantoolmesartaninhypertensivepatientswithtype2diabetesthecotostudy
AT fukunagakensaku differenceintheeffectsofswitchingfromcandesartantoolmesartanortelmisartantoolmesartaninhypertensivepatientswithtype2diabetesthecotostudy
AT ohshimatomie differenceintheeffectsofswitchingfromcandesartantoolmesartanortelmisartantoolmesartaninhypertensivepatientswithtype2diabetesthecotostudy